Crystallization and Preliminary Diffraction Analysis of the CAL PDZ Domain in Complex with a Selective Peptide Inhibitor

Document Type

Article

Publication Date

5-2011

Publication Title

Acta Crystallographica. Section F - Structural Biology and Crystallization Communications

Department

Geisel School of Medicine

Abstract

Cystic fibrosis (CF) is associated with loss-of-function mutations in the CF transmembrane conductance regulator (CFTR), which regulates epithelial fluid and ion homeostasis. The CFTR cytoplasmic C-terminus interacts with a number of PDZ (PSD-95/Dlg/ZO-1) proteins that modulate its intracellular trafficking and chloride-channel activity. Among these, the CFTR-associated ligand (CAL) has a negative effect on apical-membrane expression levels of the most common disease-associated mutant ΔF508-CFT, making CAL a candidate target for the treatment of CF. A selective peptide inhibitor of the CAL PDZ domain (iCAL36) has recently been developed and shown to stabilize apical expression of F508-CFTR, enhancing net chloride-channel activity, both alone and in combination with the folding corrector corr-4a. As a basis for structural studies of the CAL-iCAL36 interaction, a purification protocol has been developed that increases the oligomeric homogeneity of the protein. Here, the co­crystallization of the complex in space group P212121, with unit-cell parameters a = 35.9, b = 47.7, c = 97.3 Å, is reported. The crystals diffracted to 1.4 Å resolution. Based on the calculated Matthews coefficient (1.96 Å3 Da-1), it appears that the asymmetric unit contains two complexes.

DOI

10.1107/S1744309111009985

Original Citation

Amacher JF, Cushing PR, Weiner JA, Madden DR. Crystallization and preliminary diffraction analysis of the CAL PDZ domain in complex with a selective peptide inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 May 1;67(Pt 5):600-3. doi: 10.1107/S1744309111009985. Epub 2011 Apr 28. PMID: 21543871; PMCID: PMC3087650.

Link to Full Text

Share

COinS